Use of Recombinant Factor VII as a Prophylactic Therapy for Adolescent Females With Heavy Menstrual Bleeding

CompletedOBSERVATIONAL

Enrollment

Participants

Timeline

Start Date

January 15, 2023

Primary Completion Date

February 2, 2024

Study Completion Date

February 5, 2024

Conditions

Assessing the Bleeding Profile and the Quality of Life of the Enrolled Patients Before and 1 Year After Drug Intervention

Interventions

DRUG

Proph7

Prophylactic recombinant FVII for heavily menorrhagic adolescent Glanzmanns Thrombaesthenia females

Trial Locations (1)

Gehan Lotfy Abdel Hakeem, Al Minyā

All Listed Sponsors

lead

Minia University Hospital

OTHER